#31 - Navdeep Chandel, Ph.D.: metabolism, mitochondria, and metformin in health and disease

Episode Summary

Executive Summary: Peter Attia and Navdeep Chandel explore mitochondria as more than cellular powerhouses: they are signaling organelles that influence immunity, cell death, cancer, aging, and metabolism. The conversation challenges antioxidant dogma, reframes metformin as a weak mitochondrial inhibitor with potential anti-inflammatory and anti-cancer effects, and questions whether mitochondrial decline in aging is adaptive rather than purely harmful.

Main Topics: Mitochondria as signaling organelles (Priority: 5/5): Chandel argues mitochondria do not merely make ATP; they also send signals via ROS, cytochrome C, and metabolites that regulate immunity, exercise adaptation, and cell fate. Reactive oxygen species and antioxidants (Priority: 5/5): The discussion reframes ROS as context-dependent signaling molecules rather than purely toxic byproducts, and critiques broad antioxidant supplementation as potentially harmful in some settings. Apoptosis, ferroptosis, and cancer biology (Priority: 5/5): Cytochrome C release triggers apoptosis, while ROS plus iron can drive ferroptosis. These pathways are central to tumor suppression and to understanding why cancer cells resist death. Metformin and mitochondrial complex I (Priority: 5/5): Metformin is presented as a weak complex I inhibitor that lowers hepatic glucose output, activates AMPK, may reduce inflammation, and may have anti-cancer effects through mitochondrial stress. Mitochondrial DNA, inheritance, and evolution (Priority: 4/5): The guests discuss why mitochondria retain 37 genes, why mtDNA is maternally inherited, and how mitochondrial vulnerability may contribute to disease and immune activation. Aging, NAD, and metabolic decline (Priority: 4/5): They debate whether age-related declines in mitochondrial function and NAD are causal or adaptive, and whether NAD-boosting supplements meaningfully change physiology. Cancer metabolism and therapeutic targeting (Priority: 5/5): The conversation revisits Warburg metabolism, argues mitochondria remain necessary for tumor growth, and highlights emerging drugs that target mitochondrial respiration or the TCA cycle.

Key Arguments: Mitochondria are not just ATP factories; they actively regulate cell signaling, immune responses, and death decisions through ROS, cytochrome C, and metabolites. ROS are not universally bad; at physiological levels they can support immune function and exercise-induced adaptation, so indiscriminate antioxidant use may blunt beneficial biology. High-dose antioxidant trials have often failed or caused harm in contexts like sepsis, cancer, and exercise adaptation, suggesting the pro-oxidant/antioxidant balance matters. Metformin likely works by weakly inhibiting mitochondrial complex I, lowering the NADH/NAD ratio, activating AMPK, and reducing hepatic glucose production. Metformin’s possible anti-cancer and anti-inflammatory effects may stem from mitochondrial stress responses rather than direct mTOR inhibition. Cancer cells still require functional mitochondria; glycolysis alone is not sufficient for tumorigenesis, and mitochondrial respiration appears necessary in many models. Mitochondrial DNA is highly vulnerable because it is relatively unprotected and sits near ROS production, yet mitochondria maintain strong local antioxidant defenses to protect it. Age-related mitochondrial decline may be adaptive rather than purely pathological, and reduced mitochondrial activity could sometimes trigger protective stress responses. NAD-boosting supplements may increase total NAD but may not meaningfully alter the NAD/NADH redox ratio that governs mitochondrial signaling and metabolism. A new framework may be needed for disease: metabolite toxicity, not just proteotoxicity, could contribute to neurodegeneration and other chronic diseases.

Data Points: Mitochondrial genome size: 37 genes - Chandel notes mitochondria retain 37 genes, including 13 essential respiratory-chain genes. Essential mitochondrial genes: 13 genes - These 13 mitochondrial genes are required for respiratory chain function and ATP generation. Human nuclear genes: ~20,000 genes - Used as contrast with the much smaller mitochondrial genome. Key discovery year for cytochrome C release: 1996 - Zhao Dong Wang’s finding that cytochrome C release from mitochondria triggers cell death. First mitochondrial signaling paper: 1998 - Chandel says his group published evidence that mitochondrial H2O2 can function as a signaling molecule. Ferroptosis discovery: 2011 - He cites Brent Stockwell and Scott Dixon’s work identifying ferroptosis as a ROS/iron-driven cell death pathway. Mitochondrial respiratory complexes: 5 complexes - Discussed in the context of the electron transport chain and metformin’s effects on complex I. Metformin use: ~300 million people - Chandel describes metformin as a very widely used anti-diabetic drug. Estimated metformin use: ~500 million people - He notes projections as diabetes prevalence rises globally. PREDIMED trial size: ~7,500 participants - Attia references the Mediterranean diet trial in the nutrition discussion. PREDIMED arms: 3 groups - Two Mediterranean diet arms and one low-fat control arm. PREDIMED follow-up: ~4.7 years - The trial was stopped early because the Mediterranean arms outperformed control. Mitochondrial DNA deletions with age: Present - Chandel says aging is associated with mtDNA loss/deletions and reduced maximal oxidative phosphorylation. Complex I/III knockout effect in tumors: Tumors shrink or fail to grow - Genetic experiments showed respiratory-chain loss impairs tumorigenesis. L2-hydroxyglutarate trigger: High NADH / low NAD - Chandel proposes this metabolite may rise when mitochondrial function is severely impaired.

Pivotal Quotes: "Mitochondria as signaling organelles" — Navdeep Chandel: Chandel’s framing of the field and the title of his talks. "If you inhibit the respiratory chain completely, you can never turn on the cytokines." — Navdeep Chandel: Explaining why some mitochondrial ROS are necessary for immune signaling. "Mitochondria are necessary for tumor genesis." — Navdeep Chandel: Summarizing his view that functional mitochondria are required for many cancers to grow.

Implications: The episode pushes listeners to rethink mitochondria, ROS, antioxidants, metformin, and aging as context-dependent systems rather than simple good/bad binaries. It suggests future therapies may target mitochondrial signaling, inflammation, and metabolism more precisely.